Aytu BioPharma (AYTU) announced the appointment of Dr. Gerwin Westfield, PhD as Senior Vice President of Scientific Affairs, effective June 30, 2025. In his role, Dr. Westfield will oversee the Company’s medical and scientific affairs strategies, with a primary focus on the upcoming commercial launch of EXXUA extended-release tablets, a novel, branded, United States Food and Drug Administration approved treatment for major depressive disorder in adults in the United States. Westfield previously served with the Company from 2015 to 2021, including as Director of Medical Affairs. Most recently, he was Vice President of Medical Affairs for Everly Health
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AYTU:
- Aytu BioScience Expands Lending Agreement for EXXUA Launch
- Aytu BioPharma expands, extends lending agreement with Eclipse
- Aytu BioPharma’s Strategic Acquisition of EXXUA Drives Buy Rating and Raises Price Target
- Aytu BioPharma Closes $16.6M Stock Offering for EXXUA
- Aytu BioScience Signs Exclusive Agreement for EXXUA